Retinal Pigment Epithelial Tear After Intravitreal Ranibizumab (Lucentis^®) for Retinal Angiomatous Proliferation (RAP) Associated with Pigment Epithelial Detachment

Abstract

Purpose: To report a case of retinal pigment epithelial tear after intravitreal injection of ranibizumab (Lucentis^®) for retinal angiomatous proliferation (RAP).

Methods: Interventional case report.

Results: An 81-year-old woman was treated with intravitreal ranibizumab for stage-II RAP with retinal pigment epithelial (RPE) detachment. Ten days after this antiangiogenic therapy a RPE tear was detected, though no change in visual acuity occurred.

Conclusion: RPE tear may be a complication of intravitreal anti-VEGF therapy with ranibizumab. The presence of a vascularized RPE detachment increases the risk and must be considered when using these new intravitreal injections.

KEYWORDS::

• age-related macular degeneration
• RAP
• Lucentis^®
• RPE tear

ACKNOWLEDGMENT

Declaration of Interest: The authors indicate no financial conflict of interest.